MAIA Biotechnology closes $5.75M public offering to fund THIO trials and R&D

MAIA Biotechnology, Inc.

Gross proceeds of ~$5.75M from 2,555,500 shares at $2.25/share, including full over-allotment exercise.
Net proceeds of ~$5.1M after underwriting discounts and expenses; intended for THIO trials and telomere compound development.
Representative's warrants to purchase up to 127,775 shares at $2.8125/share, exercisable from Oct 2023 to Apr 2028.
ThinkEquity acted as sole book-running manager for the offering.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at aggregate net proceeds of approximately $5.1 million (effective 2023-04-24).

Action: entry
Agreement: underwriting
Counterparty: ThinkEquity LLC
Value: aggregate net proceeds of approximately $5.1 million
Effective: 2023-04-24

Exact text from the filing

On April 24, 2023, MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as representative (the “Representative”) of the several underwriters identified therein

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-006505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.